A Randomized, Double-Blind, Controlled, Parallel Group, 12-Week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 microg Once Daily With Open Label Tiotropium 18 microg Once Daily Versus Open Label Tiotropium 18 microg Once Daily in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease.

Trial Profile

A Randomized, Double-Blind, Controlled, Parallel Group, 12-Week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 microg Once Daily With Open Label Tiotropium 18 microg Once Daily Versus Open Label Tiotropium 18 microg Once Daily in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Indacaterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms INTRUST-2
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Aug 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 18 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 May 2011 Results presented at the 107th International Conference of the American Thoracic Society, according to a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top